Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness

Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker, which has been shown to not only correlate with traditional biomarkers but also outperform CRP at prognosticating CVD. More clinical trials on suPAR is in the future research agenda.

Detalles Bibliográficos
Autores principales: Cyrille, Nicole B., Villablanca, Pedro A., Ramakrishna, Harish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Expert Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900352/
https://www.ncbi.nlm.nih.gov/pubmed/27052059
http://dx.doi.org/10.4103/0971-9784.179588
Descripción
Sumario:Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker, which has been shown to not only correlate with traditional biomarkers but also outperform CRP at prognosticating CVD. More clinical trials on suPAR is in the future research agenda.

Ejemplares similares